



## Seres Therapeutics to Present at Upcoming Virtual Investor Conferences

May 25, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 25, 2021-- [Seres Therapeutics, Inc.](#), (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will present a corporate overview at two upcoming investor conferences:

- **Jefferies Virtual Healthcare Conference** at 2:30 p.m. ET on Tuesday, June 1, 2021
- **Goldman Sachs 42nd Annual Global Healthcare Conference** at 11:20 a.m. ET on Tuesday, June 8, 2021

An audio webcast of each presentation will be available under the "Investors and News" section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

### About Seres Therapeutics

Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres' SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent *C. difficile* infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres' SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and plans to initiate a clinical program with SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit [www.serestherapeutics.com](http://www.serestherapeutics.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210525005007/en/): <https://www.businesswire.com/news/home/20210525005007/en/>

### PR Contact

Kristin Ainsworth

[kainsworth@serestherapeutics.com](mailto:kainsworth@serestherapeutics.com)

### IR Contact

Carlo Tanzi, Ph.D.

[ctanzi@serestherapeutics.com](mailto:ctanzi@serestherapeutics.com)

Source: Seres Therapeutics, Inc.